...
首页> 外文期刊>Antimicrobial Resistance and Infection Control >Optimizing antimicrobial prescribing: Are clinicians following national trends in methicillin-resistant staphylococcus aureus (MRSA) infections rather than local data when treating MRSA wound infections
【24h】

Optimizing antimicrobial prescribing: Are clinicians following national trends in methicillin-resistant staphylococcus aureus (MRSA) infections rather than local data when treating MRSA wound infections

机译:优化抗菌药物处方:在治疗MRSA伤口感染时,临床医生是否遵循耐甲氧西林金黄色葡萄球菌(MRSA)感染的国家趋势而不是本地数据

获取原文
           

摘要

Background Clinicians often prescribe antimicrobials for outpatient wound infections before culture results are known. Local or national MRSA rates may be considered when prescribing antimicrobials. If clinicians prescribe in response to national rather than local MRSA trends, prescribing may be improved by making local data accessible. We aimed to assess the correlation between outpatient trends in antimicrobial prescribing and the prevalence of MRSA wound infections across local and national levels. Methods Monthly MRSA positive wound culture counts were obtained from The Surveillance Network, a database of antimicrobial susceptibilities from clinical laboratories across 278 zip codes from 1999–2007. Monthly outpatient retail sales of linezolid, clindamycin, trimethoprim-sulfamethoxazole and cephalexin from 1999–2007 were obtained from the IMS Health XponentTM database. Rates were created using census populations. The proportion of variance in prescribing that could be explained by MRSA rates was assessed by the coefficient of determination (R2), using population weighted linear regression. Results 107,215 MRSA positive wound cultures and 106,641,604 antimicrobial prescriptions were assessed. The R2 was low when zip code-level antimicrobial prescription rates were compared to MRSA rates at all levels. State-level prescriptions of clindamycin and linezolid were not correlated with state MRSA rates. The variance in state-level prescribing of clindamycin and linezolid was correlated with national MRSA rates (clindamycin R2?=?0.17, linezolid R2?=?0.22). Conclusions Clinicians may rely on national, not local MRSA data when prescribing clindamycin and linezolid for wound infections. Providing local resistance data to prescribing clinicians may improve antimicrobial prescribing and would be a possible target for future interventions.
机译:背景技术临床医生通常在了解培养结果之前就门诊伤口感染开药。处方抗菌药物时,可以考虑当地或国家的MRSA发生率。如果临床医生根据国家而不是当地的MRSA趋势开具处方,则可以通过访问本地数据来改善处方。我们旨在评估门诊抗菌药物处方趋势与地方和国家各级MRSA伤口感染率之间的相关性。方法:1999年至2007年间,来自The Surveillance Network的MRSA阳性创面培养月度计数来自The Surveillance Network,该数据库来自临床实验室的278个邮政编码的抗菌药敏感性。从IMS Health Xponent TM 数据库获得了利奈唑胺,克林霉素,甲氧苄氨磺胺甲基异恶唑和头孢氨苄在1999-2007年的月门诊零售额。使用人口普查人口创建费率。使用总体加权线性回归,通过确定系数(R 2 )评估可以由MRSA率解释的处方方差比例。结果评估了107,215 MRSA阳性伤口培养物和106,641,604抗菌处方。将邮政编码级别的抗菌药物处方率与所有级别的MRSA比率进行比较时,R 2 较低。克林霉素和利奈唑胺的国家级处方与州MRSA发生率无关。克林霉素和利奈唑胺的国家水平处方方差与全国MRSA发生率相关(克林霉素R 2 α=?0.17,利奈唑胺R 2 ?=?0.22)。结论临床医生在处方克林霉素和利奈唑胺治疗伤口感染时可能依赖于国家的而不是当地的MRSA数据。向处方医生提供局部耐药性数据可能会改善抗菌药物处方,并可能成为未来干预措施的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号